IHCAI – DIME. Información seleccionada sobre intervenciones para el tratamiento de COVID-19
In this article, a 48-year-old man with covid 19 was studied, who on the 10th day began to experience stabbing pain in his first right metatarsal joint, the patient had no history of gout until this presentation.
Colchicine is a safe oral anti-inflammatory drug that is widely used in systemic inflammatory diseases such as acute gout.
The use of colchicine in this patient not only alleviated the gout flare, but also caused the regression of all clinical symptoms and inflammatory markers.
They planned to include the following types of studies: randomized controlled trials (RCTs); quasi-randomized; non-randomized controlled trials; prospective cohort studies; retrospective cohort studies; cross-sectional studies; controlled before and after studies.
They searched for studies comparing antimicrobial mouthwash and / or nasal spray (alone or in combination) at any concentration, administered at any frequency or dose to patients with suspected / confirmed COVID-19.
No completed ...
Forty records reporting 36 unique studies were included. They reported that in general, travel restrictions can limit the spread of the disease across national borders.
However, it is likely that entry and exit screening measures alone are not effective in detecting a significant proportion of cases in order to avoid seeding new cases in the protected region, but in combination with quarantine, observation and subsequent PCR tests, effectiveness is likely to improve.
There was insufficient ...
Systematic reviews have been conducted on the usefulness of traditional chinese medicine based on herbal medicina in patients with Covid-19. The conclusions are that they may improve the symptoms and other outcomes of these patients, but this systematic review has included few studies and has been limited to the effect of traditional chinese medicine in patients with mild-moderate infection.
Alternative or combined measures should be sought to avoid creating perverse incentives in policy development e.g. penalising countries with the best testing regimen.For countries in Europe we were able to obtain from the European Centre for Disease Control 1) (7-day covid-19 case rate (2)7-day covid-19 hospital admission rate. We took population size from the same data source.